GP
CLVS

GLG Partners’s Clovis Oncology, Inc. CLVS Stock Holding History

GLG Partners’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$128K Sell
1,886
-347
-16% -$24.3K 0.01% 403
2017
Q3 		$184K Buy
+2,233
New +$177K 0.01% 309
2015
Q4 		– Sell
-38,410
Closed -$3.53M – 538
2015
Q3 		$3.53M Buy
38,410
+3,410
+10% +$295K 0.09% 220
2015
Q2 		$3.08M Buy
+35,000
New +$3M 0.08% 248
2015
Q1 		– Sell
-28,931
Closed -$1.62M – 468
2014
Q4 		$1.62M Sell
28,931
-709
-2% -$37.3K 0.05% 269
2014
Q3 		$1.34M Buy
+29,640
New +$1.24M 0.03% 327

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $7.71B AUM 4.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

GLG Partners's CLVS Position: Q4 2017 in Review

GLG Partners reduced its Clovis Oncology, Inc. (CLVS) stake by 16% in Q4 2017, selling an estimated $24.3K and leaving 1,886 shares worth $128K. The position accounts for 0.01% of the portfolio, ranked #403.

GLG Partners first reported a position in CLVS in Q3 2014 and has held it in 6 quarters since. The position peaked at $3.53M in Q3 2015. 247 funds tracked by Wall St. Rank hold CLVS as of Q4 2017.

  • GLG Partners held 1,886 shares of Clovis Oncology, Inc. worth $128K as of Q4 2017.
  • GLG Partners sold 347 Clovis Oncology, Inc. shares in Q4 2017, an estimated $24.3K.
  • Clovis Oncology, Inc. made up 0.01% of GLG Partners's portfolio in Q4 2017, its #403 holding.
  • GLG Partners first reported a position in Clovis Oncology, Inc. in Q3 2014 and has held it in 6 quarters since.
  • GLG Partners's Clovis Oncology, Inc. position peaked at $3.53M in Q3 2015.
  • 247 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2017.

Based on GLG Partners's 13F filing for Q4 2017, filed 14 Feb 2018.